Health TrialsbyHealthPanel

Physiological Effects of ANGPTL3 Variants in Humans

ConditionHypocholesterolemia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Pennsylvania

About this trial

To evaluate the role of ANGPTL3, on lipid metabolism. To explore the role of this protein on glucose metabolism.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Subjects aged 18 or older meeting at least one of the following criteria

Carrying genetic variants in the gene encoding for ANGPTL3,

Unaffected controls matched for age, race, gender,

Willing to follow study procedures

Disqualifiers

Any medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study, or confound the study data

Taking any medication that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study, or confound the study data

Women that are pregnant or nursing

History of liver disease or abnormal liver function tests (>2x upper limit of normal)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.

    Other intervention

    Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: VariantExperimental treatment 1 intervention
Group B: Non-variantOther 1 intervention

Trial outcomes

Primary outcomes

1

The role of ANGPTL3 on lipid metabolism.

Assessing ApoB-containing lipoprotein fractional catabolic rate

Time frame
through study completion, an average of 13 weeks
2

The role of this protein on glucose metabolism.

Looking for glucose area under the curve following Oral Glucose Tolerance Test

Time frame
through study completion, an average of 13 weeks
3

The role of ANPTL3 on fatty acids

Looking for fatty acids area under the curve following Oral Fat Tolerance Test

Time frame
through study completion, an average of 13 weeks

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Pennsylvania

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Source ClinicalTrials.gov
Apply now